Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Should You Buy?

Key Points

• Shares of Telix gapped up pre-market from $10.54 to $11.03 and last traded at $11.1850 on volume of 185,091, and analysts hold a consensus Moderate Buy rating with an average price target of $21.13 after several upgrades (e.g., Citigroup $22.50).
• Telix significantly missed quarterly estimates, reporting EPS of ($0.01) versus $0.05 expected and revenue of $206.7M versus $421.5M expected, highlighting a disconnect between recent analyst optimism and near-term results.
• The company shows modest liquidity and leverage (quick ratio 1.27, current ratio 1.43, debt/equity 1.08), 50-/200-day moving averages of $7.90 and $8.71 respectively, and several institutions have recently added or initiated small stakes.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $10.54, but opened at $11.03. Telix Pharmaceuticals shares last traded at $11.1850, with a volume of 185,091 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TLX. Citigroup increased their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a "buy" rating in a research note on Tuesday, February 24th. Wall Street Zen raised Telix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. Royal Bank Of Canada raised Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research note on Monday, January 19th. Wedbush reissued an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Telix Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $21.13.

Telix Pharmaceuticals Stock Performance

The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The business has a fifty day moving average of $7.90 and a two-hundred day moving average of $8.71.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last released its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million during the quarter, compared to analyst estimates of $421.50 million. As a group, equities research analysts forecast that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of TLX. Rhumbline Advisers grew its holdings in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock valued at $25,000 after buying an additional 1,392 shares during the last quarter. XTX Topco Ltd acquired a new stake in Telix Pharmaceuticals during the 4th quarter valued at $89,000. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $213,000. OLD Mission Capital LLC acquired a new stake in Telix Pharmaceuticals during the 4th quarter valued at $111,000. Finally, JPMorgan Chase & Co. acquired a new stake in Telix Pharmaceuticals during the 3rd quarter valued at $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.